Recommended by NICE and SMC1,2
POLIVY + R-Benda is indicated for the treatment of adult patients with relapsed/refractory diffuse
large B-cell lymphoma who are not candidates for haematopoietic stem cell transplant3

Find out how POLIVY + R-Benda could offer patients more time to appreciate life vs R-Benda alone4,5

More

Where could POLIVY fit in the treatment of R/R DLBCL? View the treatment algorithm

More

Learn about the manageable adverse event profile of POLIVY + R-Benda vs R-Benda alone4,5

More

Find out how POLIVY delivers a potent cytotoxic agent directly to B cells6

More

See practical guidance on the dosing and administration of POLIVY + R-Benda

More

Listen to insights on high-grade lymphoma, as discussed by experts in the field

More

R/R, relapsed/refractory; DLBCL, diffuse large B-cell lymphoma; MOA, mode of action; NICE, National Institute for Health and Care Excellence; SMC, Scottish Medicines Consortium;
R-Benda, rituximab and bendamustine.

 

References:

  1. NICE Final Appraisal Document. Available at www.nice.org.uk/guidance/gid-ta10463/documents/final-appraisal-determination-document (accessed June 2021).
  2. SMC Advice on new medicines. SMC2282. Available at https://www.scottishmedicines.org.uk/media/5360/polatuzumab-vedotin-polivy-final-august-2020-amended-180820-for-website.pdf (accessed June 2021).
  3. POLIVY Summary of Product Characteristics.
  4. Sehn LH et al. J Clin Oncol 2020;38(2):155–165.
  5. Sehn LH et al. Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension [Abstract 3020]. Presented at the 62nd ASH annual meeting, December 7, 2020.
  6. Dornan D et al. Blood 2009;114(13):2721–2729.
 
 
M-GB-00003587
Date of preparation: June 2021